{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021086","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.047098+00:00","generated_at":"2026-06-05T11:19:07.920368+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax reports FY2023 net loss $209.4M; axatilimab PDUFA Aug 28, 2024; cash $600M through 2026","bullets":["Net loss for FY2023: $209.4M ($2.98 per share) vs $149.3M ($2.46 per share) in 2022.","Cash and investments: $600.5M as of Dec 31, 2023, expected to fund operations through 2026.","BLA for axatilimab in chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.","NDA for revumenib in R/R KMT2Ar acute leukemia submitted under RTOR; PDUFA date expected 1Q24.","Enrollment in AUGMENT-101 mNPM1 cohort to complete late 1Q/early 2Q; topline data in 4Q24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021086","json":"https://secwatch.observer/filing/0000950170-24-021086.json","markdown":"https://secwatch.observer/filing/0000950170-24-021086.md","text":"https://secwatch.observer/filing/0000950170-24-021086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/0000950170-24-021086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/sndx-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:19:07.920368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"132b92a0f5b2031fa2b8e922af38f3e53d3a0d6e","claim":"Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/0000950170-24-021086-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}